Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma
Authors:
- Hiroaki MatsumotoHMHiroaki Matsumoto
- Kaoru TsuchiyaKTKaoru Tsuchiya
- Hiroyuki NakanishiHNHiroyuki Nakanishi
- Yuka HayakawaYHYuka Hayakawa
- Yutaka YasuiYYYutaka Yasui
- Naoki UchiharaNUNaoki Uchihara
- Keito SuzukiKSKeito Suzuki
- Yuki TanakaYTYuki Tanaka
- Haruka MiyamotoHMHaruka Miyamoto
- Shun IshidoSIShun Ishido
- Michiko YamadaMYMichiko Yamada
- Taisei KeitokuTKTaisei Keitoku
Open Access
Abstract
Background: Sarcopenia is associated with overall survival in patients with hepatocellular carcinoma (HCC). However, it is not known whether muscle volume is associated with clinical outcomes during combination therapy with immune checkpoint inhibitors. We investigated the relationship between changes in muscle volume and treatment outcomes in patients treated with atezolizumab plus bevacizumab. Methods: Thirty-two patients with HCC who received atezolizumab plus bevacizumab as the first-line treatment between October 2020 and February 2022 were included. Skeletal muscle mass index (SMI) was calculated from the skeletal muscle area at the L3 level of the lumbar vertebrae. We compared pretreatment SMI and SMI at 6–14 weeks after administration. Results: Of the 32 patients, 18 had a decreased SMI, while 14 did not. Progression-free survival (PFS) was significantly longer in patients without SMI decrease than in patients with SMI decrease (8.5 vs. 5.8 months, p = 0.011). There were no significant differences in treatment-related adverse events between the patients with and without SMI. Presarcopenia at baseline was not significantly associated with PFS. Conclusions: Decreased SMI was significantly associated with PFS. Monitoring muscle volume during atezolizumab plus bevacizumab therapy is useful in clinical practice.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP19fk0210025h0003)
This publication has 32 references indexed in Scilit:
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialThe Lancet, 2018
- Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic FunctionLiver Cancer, 2017
- Sarcopenia Impairs Prognosis of Patients with Hepatocellular Carcinoma: The Role of Liver Functional Reserve and Tumor-Related Factors in Loss of Skeletal Muscle VolumeNutrients, 2017
- AASLD guidelines for the treatment of hepatocellular carcinomaHepatology, 2017
- Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenibHepatology Research, 2016
- Impact of branched‐chain amino acid supplementation on survival in patients with advanced hepatocellular carcinoma treated with sorafenib: A multicenter retrospective cohort studyHepatology Research, 2015
- Body Composition Assessment in Axial CT Images Using FEM-Based Automatic Segmentation of Skeletal MuscleIEEE Transactions on Medical Imaging, 2015
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI GradeJournal of Clinical Oncology, 2015
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008